Xcout Intel
TILT Biotherapeutics
TILT Biotherapeutics is a Finnish biotechnology company developing tumor-targeted immunotherapies, including oncolytic adenoviruses designed to stimulate immune responses against solid tumors. Its therapies are intended for cancer patients and are developed through clinical and pharmaceutical partnerships.
Subscribe to see TILT Biotherapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
TILT Biotherapeutics at a glance
TILT Biotherapeutics is a biotech company headquartered in Finland. Xcout tracks 12 named people at TILT Biotherapeutics, including Aino Kalervo (Chief Executive Officer).
TILT Biotherapeutics leadership
- Aino KalervoChief Executive Officer
- Suvi SorsaChief Operating Officer
- Gianfranco PittariChief Medical Officer
- Arto LinnervuoChairman of the Board of Directors, Legal Advisor
- Akseli HemminkiFounder & CEO and Member of the Board of Directors
- Hanna KirkVP Product Development
6 more named people on record for TILT Biotherapeutics, with roles, board committees and tenure — see the full roster →
TILT Biotherapeutics competitors
A few of TILT Biotherapeutics's closest competitors — see the full list of competitors and alternatives →
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Zelluna is a Norwegian biotechnology company developing T-cell receptor (TCR)-based natural killer (NK) cell therapies for cancer, with a focus on treating solid tumors. Its products are intended for oncology patients, particularly those with cancers that are difficult to treat using existing immunotherapies.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel T cell receptor engineered T cell therapies to fight cancer. The company is involved in biotechnology research and has a presence in Berlin, Germany.
Get TILT Biotherapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on TILT Biotherapeutics in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access